PMC5783142_01
Advanced medullary thyroid carcinoma before treatment with apatinib.. Notes: (A) Both lungs with multiple metastases. (B) Mediastinal lymph node metastasis. (C) Multiple liver metastases. (D) Hilar lymph nodes.
ott-11-459Fig1.jpg
PMC5783142_01_ott-11-459Fig1.jpg
f1-ott-11-459
CEA was 10,580.00 ng/mL. CT scans revealed that both lungs had multiple metastases, mediastinal lymph node metastasis, multiple liver metastases, and hilar lymph nodes (Figure 1).
Advanced medullary thyroid carcinoma after 8 weeks of treatment with apatinib.. Notes: (A) Both lungs with multiple metastases. (B) Mediastinal lymph node metastasis. (C) Multiple liver metastases. (D) Hilar lymph nodes.
ott-11-459Fig2.jpg
PMC5783142_01_ott-11-459Fig2.jpg
f2-ott-11-459
Stable disease was observed during CT re-examination at week 8 (Figure 2).
Advanced medullary thyroid carcinoma after 16 weeks of treatment with apatinib.. Notes: (A) Both lungs with multiple metastases. (B) Mediastinal lymph node metastasis. (C) Multiple liver metastases. (D) Hilar lymph nodes.
ott-11-459Fig3.jpg
PMC5783142_01_ott-11-459Fig3.jpg
f3-ott-11-459
Partial response (PR) was observed at week 16 (Figure 3) and the concentrations of serum calcitonin and CEA continued to decline (4,476.50 pg/mL and 1,865.00 ng/mL, respectively).